The National Medical Products Administration of China (NMPA) released the news on Feb. 25 that the Rituximab Injection (trade name: Hanlikang) under Shanghai Henlius Biotech, Inc. has been approved for marketing. This is of a milestone meaning as it is the approval of the first Chinese-produced biosimilar, which has rapidly aroused heated discussions in the medical world.
